Affinity Asset Advisors LLC grew its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 220.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,000 shares of the company’s stock after purchasing an additional 55,000 shares during the quarter. Affinity Asset Advisors LLC owned approximately 0.20% of Achilles Therapeutics worth $783,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in ACHL. BlackRock Inc. purchased a new stake in Achilles Therapeutics in the first quarter worth about $413,000. JPMorgan Chase & Co. purchased a new stake in shares of Achilles Therapeutics during the first quarter valued at about $10,356,000. Monashee Investment Management LLC purchased a new stake in shares of Achilles Therapeutics during the first quarter valued at about $2,069,000. Sphera Funds Management LTD. purchased a new stake in shares of Achilles Therapeutics during the first quarter valued at about $4,965,000. Finally, Pinz Capital Management LP purchased a new stake in shares of Achilles Therapeutics during the first quarter valued at about $103,000. 46.24% of the stock is owned by institutional investors.
Shares of NASDAQ:ACHL traded down $0.03 during midday trading on Thursday, reaching $8.07. 14 shares of the company’s stock traded hands, compared to its average volume of 369,098. Achilles Therapeutics plc has a 1 year low of $5.45 and a 1 year high of $18.95. The company has a current ratio of 17.21, a quick ratio of 17.21 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $6.68 and a two-hundred day simple moving average of $9.99.
ACHL has been the topic of several recent analyst reports. Chardan Capital restated a “buy” rating on shares of Achilles Therapeutics in a report on Wednesday, July 7th. Zacks Investment Research upgraded shares of Achilles Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, July 19th. Finally, Piper Sandler cut their price target on shares of Achilles Therapeutics from $25.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, August 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $20.80.
Achilles Therapeutics Company Profile
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Recommended Story: Average Daily Trade Volume – What You Need to Know
Want to see what other hedge funds are holding ACHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achilles Therapeutics plc (NASDAQ:ACHL).
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.